...
机译:慢性骨髓白血病(CML)的Ponatinib:欧洲专家小组的患者治疗和管理达成共识
Institute for Hematology and Oncology (IHO GmbH);
Hematology Department Hospital Clinic IDIBAPS;
Department of Hematology;
Department of Hematology VU University Medical Center;
Imperial College London Department of Medicine;
Department of Hematology;
Department of Hematology and Oncology “L. and A. Seràgnoli ” St Orsola-Malpighi Hospital;
BCR-ABL1; Chronic myeloid leukemia; Philadelphia chromosome; Ponatinib; Tyrosine kinase inhibitor;
机译:慢性骨髓白血病(CML)的Ponatinib:欧洲专家小组的患者治疗和管理达成共识
机译:慢性相慢性骨髓性白血病(CML-CP)患者的结果在停止前线Ponatinib治疗后
机译:Ponatinib治疗慢性骨髓白血病(CML)的结果和副作用概况:回顾性单中心体验
机译:急性和慢性骨髓白血病白血病相关抗原的表征(AML / CML)
机译:慢性粒细胞白血病(CML)中造血干细胞的特征。
机译:博舒替尼治疗慢性期慢性粒细胞白血病相关不良事件的处理:专家小组审查
机译:慢性骨髓白血病(CML)的Ponatinib:欧洲专家小组的患者治疗和管理达成共识